LoginSignup
Novavax logo

Novavax

Stock
Stock
ISIN: US6700024010
Ticker: NVAX
US6700024010
NVAX

Price

Price

Frequently asked questions

What is Novavax's market capitalization?

The market capitalization of Novavax is $1.36B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Novavax?

Novavax's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.257. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Novavax's stock?

Currently, 6 analysts cover Novavax's stock, with a consensus target price of $21.40. Analyst ratings provide insights into the stock's expected performance.

What is Novavax's revenue over the trailing twelve months?

Over the trailing twelve months, Novavax reported a revenue of $885.19M.

What is the EBITDA for Novavax?

Novavax's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$243.25M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Novavax?

Novavax has a free cash flow of -$110.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Novavax's stock?

The 5-year beta for Novavax is 2.02. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Novavax have, and what sector and industry does it belong to?

Novavax employs approximately 1,543 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Novavax's shares?

The free float of Novavax is 153.17M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $1.36B

5Y beta

 2.02

EPS (TTM)

 -$2.257

Free Float

 153.17M

Revenue (TTM)

 $885.19M

EBITDA (TTM)

 -$243.25M

Free Cashflow (TTM)

 -$110.85M

Pricing

1D span
$7.929$8.617
52W span
$3.532$23.86

Analyst Ratings

The price target is $21.40 and the stock is covered by 6 analysts.

Buy

3

Hold

3

Sell

0

Information

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

1,543

Biotechnology & Drugs

Health Care

Identifier

ISIN

US6700024010

Primary Ticker

NVAX

Knockouts

Join the conversation
Sign upLogin